Tenfoplus contains Tenofovir Alafenamide. Tenfoplus uses:

Tenfoplus is a hepatitis B virus (HBV) nucleoside analog reverse transcriptase inhibitor and is indicated for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease.

Ads
Brand Name: Tenfoplus
Generic: Tenofovir Alafenamide
Weight: 25.0 Mg
Type: Tablet
Therapeutic Class: Hepatic viral infections (Hepatitis B)
Manufacturer: ABBOTT INDIA LTD
Price: 1264.8
Last Updated: 2020-11-20 18:15:00

Doses

Tenfoplus contains Tenofovir Alafenamide 25.0 Mg. Tenfoplus doses

Testing Prior To Initiation Of Tenfoplus : Prior to initiation of Tenfoplus , patients should be tested for HIV-1 infection. Tenfoplus alone should not be used in patients with HIV infection

It is recommended that serum creatinine, serum phosphorous, estimated creatinine clearance, urine glucose, and urine protein be assessed before initiating Tenfoplus and during therapy in all patients as clinically appropriate

Recommended Dosage In Adults: The recommended dosage of Tenfoplus is 25 mg (one tablet) taken orally once daily with food

 

Side Effects

The following adverse reactions are discussed in other sections of the labeling:

  • Lactic Acidosis/Severe Hepatomegaly with Steatosis
  • Severe Acute Exacerbation of Hepatitis B
  • New Onset or Worsening of Renal Impairment

The most common side effects are headache, stomach pain, tiredness, cough, nausea, back pain

Ads
Introduction

Tenofovir alafenamide is a phosphonamidate prodrug of tenofovir (2'-deoxyadenosine monophosphate analog). Tenofovir alafenamide as a lipophilic cell-permeant compound enters primary hepatocytes by passive diffusion and by the hepatic uptake transporters OATP1B1 and OATP1B3. Tenofovir alafenamide is then converted to tenofovir through hydrolysis primarily by carboxylesterase 1 (CES1) in primary hepatocytes. Intracellular tenofovir is subsequently phosphorylated by cellular kinases to the pharmacologically active metabolite tenofovir diphosphate. 

Tenofovir diphosphate inhibits HBV replication through incorporation into viral DNA by the HBV reverse transcriptase, which results in DNA chain-termination.Tenofovir diphosphate is a weak inhibitor of mammalian DNA polymerases that include mitochondrial DNA polymerase γ and there is no evidence of toxicity to mitochondria in cell culture.

Precaution

 

Interaction

Tenofovir is a substrate of P-glycoprotein (P-gp) and BCRP. Drugs that strongly affect P-gp and BCRP activity may lead to changes in Tenofovir absorption. Consult the full prescribing information prior to and during treatment for potential drug drug interactions.

Pregnancy Lactation use

Before you take Tenfoplus , tell your healthcare provider about all of your medical conditions, including if you are pregnant or plan to become pregnant. It is not known if Tenfoplus will harm your unborn baby. Tell your healthcare provider if you become pregnant during treatment with Tenfoplus . 

Pregnancy Registry: There is a pregnancy registry for women who take antiviral medicines during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk with your healthcare provider about how you can take part in this registry.

Contraindication

None

Special Warning

Pediatric Use: Safety and effectiveness of Tenfoplus in pediatric patients less than 18 years of age have not been established.

Geriatric Use: Clinical trials of Tenfoplus did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.

Renal Impairment: No dosage adjustment of Tenfoplus is required in patients with mild, moderate, or severe renal impairment. Tenfoplus is not recommended in patients with end stage renal disease (estimated creatinine clearance below 15 mL per minute) 

Hepatic Impairment: No dosage adjustment of Tenfoplus is required in patients with mild hepatic impairment (Child-Pugh A). The safety and efficacy of Tenfoplus in patients with decompensated cirrhosis (Child-Pugh B or C) have not been established; therefore Tenfoplus is not recommended in patients with decompensated (Child-Pugh B or C) hepatic impairment

Acute Overdose

If overdose occurs, monitor patient for evidence of toxicity. Treatment of overdosage with Tenfoplus consists of general supportive measures including monitoring of vital signs as well as observation of the clinical status of the patient. Tenofovir is efficiently removed by hemodialysiswith an extraction coefficient of approximately 54%

Interaction with other Medicine

 

Storage Condition

Store below 86°F (30°C). Keep in its original container. Keep the container tightly closed.

Tenfoplus Tablet price in India 1264.8

Ads